Literature DB >> 34370345

Correlation between CD163 expression and resting pain in patients with hip osteoarthritis: Possible contribution of CD163+ monocytes/macrophages to pain pathogenesis.

Yoshihisa Ohashi1, Kentaro Uchida1, Kensuke Fukushima1, Masashi Satoh2, Tomohisa Koyama1, Maho Tsuchiya1, Hiroki Saito1, Katsufumi Uchiyama1, Naonobu Takahira3, Gen Inoue1, Masashi Takaso1.   

Abstract

Expression of CD163, a scavenger receptor specifically expressed by monocytes and macrophages, is elevated in the synovial tissue of patients with knee osteoarthritis (OA) compared with healthy controls. However, the association between CD163 expression in the synovium and pain in OA patients is unclear. We investigated the correlation between synovial CD163 expression and resting and active pain levels in patients with hip osteoarthritis (HOA). To investigate the possible contribution of CD163+ subsets to pain pathogenesis, we compared pain-related cytokine expression and M1/M2 macrophage marker expression in CD163+ and CD163- cells. We performed flow cytometric analysis to study the CD163+ cell population. We also examined pain-related cytokine expression and M1/M2 macrophage marker expression on CD163+ CD14high and CD163+ CD14low cells using cell sorting. Synovial CD163 expression significantly correlated with resting pain levels (p = 0.006; R = 0.321), but not active pain levels (p = 0.155; R = 0.169). Expression of the M1 macrophage marker CD80 was significantly higher in CD163+ than CD163- cells (p = 0.010), as was the expression of M2 macrophage markers CD206 and IL10 (CD206, p = 0.014; IL10, p = 0.005), and TNFA and IL1B (TNFA, p = 0.002; IL1B, p = 0.001). TNFA expression was significantly higher in CD163+ CD14low than CD163+ CD14high cells, while IL1B, IL10, and CD206 expression were comparable among these subsets. Our findings suggest that CD163 expression is associated with higher resting pain scores. As TNF-α plays a role in the pain process, CD163+ CD14low cells expressing TNFA may be a potent contributor to the pathogenesis of resting pain in HOA.
© 2021 Orthopaedic Research Society. Published by Wiley Periodicals LLC.

Entities:  

Keywords:  CD163+ cells; hip osteoarthritis; resting pain; tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2021        PMID: 34370345     DOI: 10.1002/jor.25157

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.102


  5 in total

Review 1.  Osteoarthritis Pain.

Authors:  Huan Yu; Tianwen Huang; William Weijia Lu; Liping Tong; Di Chen
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

2.  Gasdermin D deficiency attenuates arthritis induced by traumatic injury but not autoantibody-assembled immune complexes.

Authors:  Tong Yang; Kai Sun; Chun Wang; Gaurav Swarnkar; Songtao Quan; Dustin Kress; Jianqiu Xiao; Yael Alippe; Hongjun Zheng; Robert H Brophy; Dingjun Hao; Audrey McAlinden; Yousef Abu-Amer; Jie Shen; Gabriel Mbalaviele
Journal:  Arthritis Res Ther       Date:  2021-11-16       Impact factor: 5.156

3.  Six macrophage-associated genes in synovium constitute a novel diagnostic signature for osteoarthritis.

Authors:  Yiying Liu; Taoyuan Lu; Zaoqu Liu; Wenhua Ning; Siying Li; Yanru Chen; Xiaoyong Ge; Chunguang Guo; Youyang Zheng; Xiangyang Wei; Haiming Wang
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

4.  Expanded CD1c+CD163+ DC3 Population in Synovial Tissues Is Associated with Disease Progression of Osteoarthritis.

Authors:  Guowei Qiu; Sheng Zhong; Jun Xie; Hui Feng; Songtao Sun; Chenxin Gao; Xirui Xu; Bingxin Kang; Hui Xu; Chi Zhao; Lei Ran; A Xinyu; Bo Xu; Xiaohui Meng; Lu Meng; Xiaoming Zhang; Lianbo Xiao
Journal:  J Immunol Res       Date:  2022-08-01       Impact factor: 4.493

5.  Bibliometric and visualization analysis of macrophages associated with osteoarthritis from 1991 to 2021.

Authors:  Zhen Yang; Jianjing Lin; Hui Li; Zihao He; Kai Wang; Liandi Lei; Hao Li; Dan Xing; Jianhao Lin
Journal:  Front Immunol       Date:  2022-10-04       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.